Of these, 56 patients (6.9%) had ER-/PgR+ breast cancers, while 624 (76.6%) had ER+ tumors irrespective of PgR expression (ER+/PgR-any) and 136 (16.7%) had ER-/PgR- tumors. The gene discussed is ESR1; the disease is breast carcinoma.